Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,299
  • Shares Outstanding, K 66,497
  • Annual Sales, $ 49,590 K
  • Annual Income, $ -122,730 K
  • 60-Month Beta N/A
  • Price/Sales 3.33
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade XERS with:

Options Overview Details

View History
  • Implied Volatility 98.53% ( -0.27%)
  • Historical Volatility 112.49%
  • IV Percentile 53%
  • IV Rank 21.24%
  • IV High 254.42% on 05/13/22
  • IV Low 56.48% on 07/30/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 59
  • Volume Avg (30-Day) 144
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 35,056
  • Open Int (30-Day) 33,545

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.24
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +46.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.25 +73.60%
on 05/12/22
2.53 -14.23%
on 05/03/22
-0.27 (-11.07%)
since 04/20/22
3-Month
1.25 +73.60%
on 05/12/22
2.95 -26.44%
on 03/18/22
-0.27 (-11.07%)
since 02/18/22
52-Week
1.25 +73.60%
on 05/12/22
4.98 -56.43%
on 06/25/21
-1.33 (-38.00%)
since 05/20/21

Most Recent Stories

More News
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today...

XERS : 2.17 (-1.36%)
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology today...

XERS : 2.17 (-1.36%)
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 9.10 (+0.78%)
XERS : 2.17 (-1.36%)
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today...

XERS : 2.17 (-1.36%)
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today...

XERS : 2.17 (-1.36%)
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?...

AKBA : 0.3302 (-4.57%)
XERS : 2.17 (-1.36%)
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XERS : 2.17 (-1.36%)
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

PTCT : 32.33 (-0.52%)
XERS : 2.17 (-1.36%)
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced...

XERS : 2.17 (-1.36%)
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today...

XERS : 2.17 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 2.36
2nd Resistance Point 2.31
1st Resistance Point 2.24
Last Price 2.17
1st Support Level 2.12
2nd Support Level 2.06
3rd Support Level 1.99

See More

52-Week High 4.98
Fibonacci 61.8% 3.56
Fibonacci 50% 3.12
Fibonacci 38.2% 2.67
Last Price 2.17
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar